Cologne Conferences

Cologne, the fourth-largest city in Germany is located on both sides of the Rhine River with a population of around 1.02 million. In medieval times it was the largest city of the Holy Roman Empire. It is one of the nation's media, tourism and business hotspots. More than 60 financial institutions are represented in Cologne. One of these is the Sparkasse Köln Bonn founded over 170 years ago; it is Cologne's largest financial institution and one of the largest savings banks in Germany. Cologne is one of the leading centres for the European automotive industry Cologne is one of the warmest cities in Germany and has a temperate–oceanic climate with cool winters and warm summers.

Market Analysis & Funding  for  Pharmacy | Immunology | Neuroscience | Vaccines | Cancer |Engineering | Cardiology | Biotechnology

 in Cologne, Germany

Pharmacy        

Bayer HealthCare Pharmaceuticals located in Cologne markets its products in more than 100 countries, and in 2012 generated sales of €10,803 million. The BioCampus Cologne is developing into a motor of innovation and one of the largest pharmaceutical and biotech parks in Germany.

                Figure 1: Turn over in Top pharmaceutical companies

Immunology

In Cologne,Rigontec company is the leader in RIG-I targeting RNA therapeutics. The company has raised €14.25 million recently. Distributable profit of Bayer, the pharmaceutical giant in Germany is 2067 euro million in 2015 alone and is leading ahead in immune products.

                     Figure 2: Research on Immunological products

Neuroscience

University of Cologne includes department for neurosciences with collaborative interactions of Cologne‘s Neuroscience Research groups. The Alzheimer Forschung Initiative e.V. grants funds for research on brain sciences mainly Alzheimer’s. It grants maximum of € 80,000 for two years. The German Research Foundation provides funds for research in (Cellular Stress Responses in Aging-Associated Diseases) cluster at University of Cologne. The total funding amounts to about 120 million euros over the next five years.

       Figure 3: Global funding for neuroscience research

Vaccines

In Europe, the other major hub for biopharmaceutical CMOs, 20 CMOs have facilities located in Germany majorly working on vaccines. The Lonza Company, most-trusted suppliers to the Pharma & Biotech generated sales of CHF 3.8 billion in 2015in vaccine products. Delta-Vir GmbH is expanding the access of novel therapeutic cancer vaccine treatment in Cologne. It has developed dendritic cell vaccine work which is effective.  It also developed DVG01 vaccine to treat patients with Glioblastoma multiforme with the global market around 2.58 billion euros ($3.39 billion).

                Figure 4: Global research on vaccines (%)

Cancer

The current focus of research worldwide is Oncology. Universities in cologne have been extensively conducting research on cancer biology. Global spending on oncology medicines increased 10.3% in 2014 and reached $100 billion from $75 billion.

             Figure 5: Research activities in cancer biology(%)

Engineering

ChemCologne, Europe’s strongest chemical region generated 30.5 billion euro in the chemical industry in 2015 which is equivalent to 22% of Germany's total chemical turnover. German mechanical engineering has always been the backbone of the German economy. Over 11% of German R&D expenditure is in automotive manufacturing industry and average euro 35 bn p.a cumulative direct investments in overseas. The turnover is EUR 200 bn per annum with 11% of world machinery production. The products have 16 % of global machinery exports.

         Figure 6: Worldwide employment in engineering sector

Cardiology

The global market for interventional cardiology technologies reached an estimated $12.2 billion in 2014. According to a new study by Smithers Apex– it will grow to $22.5 billion (€20.9 billion) by 2021, with a year-on-year increase of 9.1%. Different projects in University of Cologne are funded by EU grants programmes like funding support of 11.9 M€ for 5.5 years for project on Embryonic Stem cell-based Novel Alternative Testing Strategies.

                     Figure 7: Research on cardiovascular diseases

Biotechnology

The Max Planck-Genome-centre Cologne (MP-GC) is a core facility for Max Planck Institutes performing next generation sequencing (NGS) and raises funds for various projects. The Federal Ministry of Research and Education is providing support of 60 million euros for five years in order to establish industrial biotechnology clusters as part of BioIndustries 2021 competition and from the private sector, research and development projects are expected to benefit from funding of 150 million euros.

CLIB- Cluster Industrial Biotechnology

IBP- Industrial Processes with Biogenous Building Blocks and Performance Proteins

                                       Figure 8: Funding in Biotech sector

Cologne City Highlights

Cologne has a distinguished and high-calibre research and academic community in the fields of medicine and biotechnology. There are over 20 companies in the municipality and over 40 in the region as a whole working in the biotechnology sector alone, Cologne is a best example of emerging destination for students and researchers. It is also the most popular tourist attraction with high rise structures, museums and carnival.

Universities in Cologne | Cologne Conferences

Pharma , Biotech Companies and Industries in Cologne | Cologne Conferences